Roche Holding Ltd · SIX:RO
Roche — dbAccess German Corporate Conference 2022
21 slides from Roche's conference presentation, May 24, 2022
Slide 1: Slide 1
Slide 2: Forward-looking statements
This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, str
Slide 3: 2022 – Innovation as driver
2022 – Innovation as driver Alan Hippe | CFO Roche dbAccess German Corporate Conference, Frankfurt, 24 May 2022
Slide 4: Q1 Performance update; Drive for innovation
Q1 Performance update Drive for innovation Pharma Diagnostics Outlook
Slide 5: Q1 2022: Strong underlying business momentum
Q1 2022: Strong underlying business momentum +11% at CER CHFm Diversification of Roche business +449 -568 + 749 -155 Q1 2017 Q1 2022 + 304 +736 CHF 12.9bn CHF 16.4bn AHR AHR 16,445 14,930 Diagnostics Oncology Other pharma AHR Ophthalmology Neuroscience Infectious diseases Hemophilia A Q1 Diagnostics
Slide 6: Drive for innovation
Q1 Performance update Drive for innovation Pharma Diagnostics Outlook
Slide 7: OneRoche: Reallocating resources to R&D and defending margins
OneRoche: Reallocating resources to R&D and defending margins while managing an exceptional patent cliff Roche Group growth 2021 vs. 2018 7
Slide 8: 2022: Upcoming newsflow
2022: Upcoming newsflow Pharma Diagnostics Vabysmo in DME/nAMD Automated BenchMark immunohistochemistry/in situ Susvimo in nAMD ULTRA PLUS hybridization advanced staining Ongoing and platform upcoming Polivy in 1L DLBCL launches High capacity pathology slide mosunetuzumab in FL Upcoming DP600 scanne
Slide 9: Pharma: Growing franchises & upcoming late stage read-outs
Q1 Performance update Drive for innovation Pharma: Growing franchises & upcoming late stage read-outs Diagnostics Outlook
Slide 10: Pharma: A solid base to deliver future growth
Pharma: A solid base to deliver future growth Late-stage pipeline to impact future growth momentum: mosunetuzumab, glofitamab, tiragolumab, gantenerumab, giredestrant, fenebrutinib, SRP-9001, etc. cobas 6800/8800, cobas 5800, cobas pure, cobas pro (high throughput), cobas Mass Spec, cobas Liat, etc.
Slide 11: Vabysmo & Susvimo in nAMD, DME, DR and RVO
Vabysmo & Susvimo in nAMD, DME, DR and RVO Building a global ophthalmology franchise Global retina market growing to $15b 16 14 2.4 12 2.0 Global Sales US $B 3.9 10 3.1 8 0.7 6 1.6 4 7.8 8.8 RVO 6.2 DME/DR 2 nAMD 0 • New dual MOA: Anti-VEGF/ Ang2 • First Roche intravitreal implant 2015 2020 2025E bi
Slide 12: Hematology franchise with Polivy and CD20 x CD3 bispecifics
Hematology franchise with Polivy and CD20 x CD3 bispecifics Ph III (POLARIX) results in 1L DLBCL Developing novel combinations in NHL First positive study in in 20 years DLBCL FL Progression free survival (PFS) Tilly et al, NEJM 2021 • Polivy + R-CHP significantly prolongs PFS with a HR of 0.73 in p
Slide 13: 2022 Pipeline: Tecentriq adjuvant read-outs expected
2022 Pipeline: 5 Tecentriq adjuvant read-outs expected Moving earlier in the treatment schedule Outcomes by cancer type and stage Ph III adjuvant trial program for Tecentriq & Alecensa at diagnosis 1 Post 2020 2021 2022 2022 IMpassion 031 neoadjuvant Tecentriq + nab-paclitaxel NCT02620280 (sponsor F
Slide 14: 2022 Pipeline: tiragolumab readouts in NSCLC, CC and ESCC
2022 Pipeline: 3 tiragolumab readouts in NSCLC, CC and ESCC Ph II (CITYSCAPE) results: Tiragolumab + Tecentriq in 1L PDL1+ NSCLC (n=58) Ph III trial program for tiragolumab Overall survival for TPS≥ 50% Indication Ph 1 Ph 2 Ph 3 1L NSCLC: PD-L1 high SKYSCRAPER-01 Q2 22 1L ES-SCLC SKYSCRAPER-02 Lung
Slide 15: Diagnostics: Accelerated base business growth & future opportunities
Q1 Performance update Drive for innovation Pharma Diagnostics: Accelerated base business growth & future opportunities Outlook
Slide 16: COVID business expected to have peaked in Q1
COVID business expected to have peaked in Q1 Very strong COVID-19 and base business growth 55% 48% 1 Diagnostics Division sales growth 28% 31% Routine sales growth 1 24% 18% 17% 18% 8% 10% 5% 2% 11% 1% -2% 9% -5% Q1 20 Q2 20 Q3 20 Q4 20 Q1 21 Q2 21 Q3 21 Q4 21 Q1 22 -17% COVID- Q1: 0.1bn Q2: 0.6bn Q
Slide 17: Molecular Lab installed base
Molecular Lab installed base We more than doubled our footprint in the market Installed base for cobas® 6800/8800 +138% ~1,900 ~1,770 ~1,200 ~800 2018 2019 2020 2021 Q1 2022 17
Slide 18: New innovations driving market access in years to come
New innovations driving market access in years to come Mass Spectrometry Emerging Market Analyzer First fully integrated mass spectrometry Routing testing in remote areas ● Integration of mass spec into the Core Lab ● Designed for the specific needs of emerging markets ● Sample in - result out ● Com
Slide 19: Outlook
Q1 Performance update Drive for innovation Pharma Diagnostics Outlook
Slide 20: 2022 outlook
2022 outlook Group sales growth1 • Stable to low-single digit • Low- to mid-single digit (including accretion of Core EPS growth1 4.4%p from share repurchase) Dividend outlook • Further increase dividend in Swiss francs 1 At Constant Exchange Rates (CER) 20
Slide 21: Doing now what patients need next
Doing now what patients need next
Roche Holding — dbAccess German Corporate Conference 2022 on 6ix